Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
Date:8/11/2008

CAMBRIDGE, Mass., Aug. 11 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced that the first patient has received an initial dose in a Phase 1 clinical study of the Company's first oncology product, MM-121, a fully human monoclonal antibody and a first-in-class therapeutic designed to block signaling of the ErbB3 receptor.

ErbB3 is a receptor in the ErbB family, a pathway that plays a critical role in cancer signaling. With the initiation of the Phase 1 trial, MM-121 becomes the first systems biology product as well as the first selective ErbB3 antagonist to enter human clinical development.

"We used a combination of high-throughput biology and computer simulation to discern the importance of targeting ErbB3 signaling in tumor cells," said Dr. Ulrik B. Nielsen, Senior Vice President of Research. "We believe this is the first systems-designed therapeutic in clinical development. Until now, computer simulation has not been widely applied toward understanding optimal therapeutic strategies for treating cancers driven by complex signaling pathways."

Preclinical data demonstrating the impact of MM-121 in multiple cancer models were presented at the annual meeting of the American Association for Cancer Research in April. The Phase 1 dose escalation study will evaluate the safety and pharmacokinetics (PK) of MM-121. Enrollment is underway at Fox Chase Cancer Center and two additional leading oncology sites are expected to participate in the trial later this year.

"ErbB3 is now recognized as a potentially important target in many types of cancer including lung, breast, colorectal, ovarian and others," said Dr. William J. Slichenmyer, Senior Vice President and Chief Medical Officer at Merrimack. "Preclinical studies of MM-121 have demonstrated antitumor activity in a wide range of tumor types and a very favorable safety profile. We are optimistic that these findings may translate into clinical benefit for patients who participat
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
2. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015 /CNW/ - Shell today celebrated the ... the premium category with an exhibit the size of ... included interactive demonstrations for media and the public, and ... V-Power NiTRO+ Premium Gasoline provides the best total engine ... performance: engine wear, gunk and corrosion. "With ...
(Date:6/2/2015)... DUBLIN , June 02, 2015 Research ... of the "Bioburden Testing Market by Product , ... report to their offering. The bioburden ... 2019 from $354.4 Million in 2014, growing at a ... the basis of products, the microbial limit testing market ...
(Date:6/2/2015)... DUBLIN , June 02, 2015 ... addition of Jain PharmaBiotech,s new report "Biomarkers ... offering. This report follows the broad ... can be objectively measured and evaluated as an ... well as pharmacological responses to a therapeutic intervention. ...
(Date:6/2/2015)... Calif. (PRWEB) June 02, 2015 ... build-to-order, independent blade-based and rackmount computing and storage ... announced the launch of its high density scale-out, ... Cirrascale Slipstream™ RM1622D . The high density, ... E3-1200 v4 product family with Intel® Iris™ Pro ...
Breaking Biology Technology:New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 2New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 3New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 4Bioburden Testing Market 2015 - Global Forecasts to 2019 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 2Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 3
... - Company Achieves Record First Quarter of Net Product Sales; ... Cinryze(TM) C1 Esterase Inhibitor (Human) -EXTON, Pa., April 29 ... financial results for the first quarter ended March 31, 2009., ... First quarter 2009 adjusted net income of $11.5 million, ...
... provides grant to develop blood-based, ... nasopharyngeal, cancer -,TORONTO, April 29 ... focused on developing blood-based biomarker tests for the ... today announced that it will undertake a two-year ...
... 29 , - ... Elsevier, the world,s leading publisher ... announced today that ten new eBook,Specialty Collections have ... clinical reference tool. This launch provides online availability,of ...
Cached Biology Technology:ViroPharma Incorporated Reports First Quarter 2009 Financial Results 2ViroPharma Incorporated Reports First Quarter 2009 Financial Results 3ViroPharma Incorporated Reports First Quarter 2009 Financial Results 4ViroPharma Incorporated Reports First Quarter 2009 Financial Results 5ViroPharma Incorporated Reports First Quarter 2009 Financial Results 6ViroPharma Incorporated Reports First Quarter 2009 Financial Results 7ViroPharma Incorporated Reports First Quarter 2009 Financial Results 8ViroPharma Incorporated Reports First Quarter 2009 Financial Results 9ViroPharma Incorporated Reports First Quarter 2009 Financial Results 10ViroPharma Incorporated Reports First Quarter 2009 Financial Results 11ViroPharma Incorporated Reports First Quarter 2009 Financial Results 12ViroPharma Incorporated Reports First Quarter 2009 Financial Results 13ViroPharma Incorporated Reports First Quarter 2009 Financial Results 14ViroPharma Incorporated Reports First Quarter 2009 Financial Results 15GeneNews to conduct joint project funded by MYR 5 million grant from Malaysian government 2Elsevier Launches Ten New eBook Specialty Collections on MD Consult 2Elsevier Launches Ten New eBook Specialty Collections on MD Consult 3
(Date:4/27/2015)... 2015 Profile Solutions, Inc. (OTC: PSIQ), a ... is pleased to announce that Dr Gerry Bedore ... member of its scientific advisory board. ... thought leader in technology-enhanced learning models. He was a ... published studies and books focused on online student success ...
(Date:4/20/2015)... The announcement comes as demand for fire vault ... Ireland,s foremost records management company, has secured ... impressive track record of clients within the first 12 months, ... sector in Dubai . As a result, ... a further eight staff members at its Irish headquarters. The ...
(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... method for fighting skin wrinkles has been developed at ... Quality Sciences. In her doctoral research at the ... antioxidant that delays the aging process by countering the ... conducted her research under the supervision of Zecharia ...
... of the most basic features of a living organism. ... in turn control others genes whose activity turns on ... cycle, energy production, DNA repair, cellular suicide etc). Many ... special proteins (transcription factors) to 6 - 10 nucleotide ...
... Smoking tobacco is no longer considered sexy, but it may prove ... the online open access journal BMC Genomics could help explain why ... who have never smoked. A Canadian team led by ... took samples from the lungs of 24 current and former smokers, ...
Cached Biology News:Antioxidant to retard wrinkles discovered by Hebrew University researcher 2Gene regulation in humans is closer than expected to simple organisms 2Smoking turns on genes -- permanently 2